HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA chief counsel

This article was originally published in The Rose Sheet

Executive Summary

Daniel Troy, a partner at Wiley, Rein & Fielding (Washington, D.C.), is designated the agency's top attorney. Troy is known in health care circles as one of the attorneys who successfully challenged FDA's approach under the Clinton Administration to off-label drug and medical device promotions in the Washington Legal Foundation v. Henney suit. He will report to another ex-Wiley, Rein & Fielding partner, Alex Azar, who was confirmed as HHS general counsel Aug. 3

You may also be interested in...



Deputy Chief Counsel Masoudi Will Succeed Troy In Acting Capacity

Gerald Masoudi will be FDA's acting chief counsel after Daniel Troy departs Nov. 24

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
UsernamePublicRestriction

Register

RS009554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel